Systematic review: Body composition in adults with inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 3, 2013, Pages 213-225

  Bryant, R V ^a   Trott, M J ^a   Bartholomeusz, F D ^a   Andrews, J M ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; 6 MERCAPTOPURINE DERIVATIVE; BIOLOGICAL PRODUCT; CORTICOSTEROID;

AGE; BODY COMPOSITION; BODY FAT; BODY MASS; BONE DENSITY; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; GENDER; HUMAN; LEAN BODY WEIGHT; OBESITY; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SMOKING; SYSTEMATIC REVIEW; ULCERATIVE COLITIS;

ADULT; BODY COMPOSITION; BODY MASS INDEX; BONE DENSITY; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; QUALITY OF LIFE;

EID: 84879787825     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12372     Document Type: Review

References (107)

1. Bernstein CN, Leslie WD, Leboff MS,. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124: 795-841.
2. Bernstein CN,. Osteoporosis in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4: 152-6.
3. van Hogezand RA, Hamdy NA,. Skeletal morbidity in inflammatory bowel disease. Scand J Gastroenterol Suppl 2006; 243: 59-64.
4. Pappa H, Thayu M, Sylvester F, Leonard M, Zemel B, Gordon C,. Skeletal health of children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2011; 53: 11-25.
5. Boot AM, Bouquet J, Krenning EP, de Muinck Keizer-Schrama SM, Bone mineral density and nutritional status in children with chronic inflammatory bowel disease. Gut 1998; 42: 188-94.
6. Walsh MC, Hunter GR, Livingstone MB,. Sarcopenia in premenopausal and postmenopausal women with osteopenia, osteoporosis and normal bone mineral density. Osteoporos Int 2006; 17: 61-7.
7. Bakker I, Twisk JW, Van Mechelen W, Kemper HC,. Fat-free body mass is the most important body composition determinant of 10-yr longitudinal development of lumbar bone in adult men and women. J Clin Endocrinol Metab 2003; 88: 2607-13.
8. Sirola J, Kroger H,. Similarities in acquired factors related to postmenopausal osteoporosis and sarcopenia. J Osteoporos 2011; 2011: 536735.
9. Wang MC, Bachrach LK, Van Loan M, Hudes M, Flegal KM, Crawford PB,. The relative contributions of lean tissue mass and fat mass to bone density in young women. Bone 2005; 37: 474-81.
10. Whiting SJ,. Obesity is not protective for bones in childhood and adolescence. Nutr Rev 2002; 60: 27-30.
11. Roubenoff R, Kehayias JJ,. The meaning and measurement of lean body mass. Nutr Rev 1991; 49: 163-75.
12. Hass DJ, Brensinger CM, Lewis JD, Lichtenstein GR,. The impact of increased body mass index on the clinical course of Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 482-8.
13. Fink C, Karagiannides I, Bakirtzi K, Pothoulakis C,. Adipose tissue and inflammatory bowel disease pathogenesis. Inflamm Bowel Dis 2012; 18: 1550-7.
14. Sylvester FA, Leopold S, Lincoln M, Hyams JS, Griffiths AM, Lerer T,. A two-year longitudinal study of persistent lean tissue deficits in children with Crohn's disease. Clin Gastroenterol Hepatol 2009; 7: 452-5.
15. Bin CM, Flores C, Alvares-da-Silva MR, Francesconi CF,. Comparison between handgrip strength, subjective global assessment, anthropometry, and biochemical markers in assessing nutritional status of patients with Crohn's disease in clinical remission. Dig Dis Sci 2010; 55: 137-44.
16. Wiskin AE, Wootton SA, Hunt TM, et al,. Body composition in childhood inflammatory bowel disease. Clin Nutr 2011; 30: 112-5.
17. Cuoco L, Vescovo G, Castaman R, et al,. Skeletal muscle wastage in Crohn's disease: a pathway shared with heart failure? Int J Cardiol 2008; 127: 219-27.
18. Schneider SM, Al-Jaouni R, Filippi J, et al,. Sarcopenia is prevalent in patients with Crohn's disease in clinical remission. Inflamm Bowel Dis 2008; 14: 1562-8.
19. Valentini L, Schaper L, Buning C, et al,. Malnutrition and impaired muscle strength in patients with Crohn's disease and ulcerative colitis in remission. Nutrition 2008; 24: 694-702.
20. Filippi J, Al-Jaouni R, Wiroth JB, Hebuterne X, Schneider SM,. Nutritional deficiencies in patients with Crohn's disease in remission. Inflamm Bowel Dis 2006; 12: 185-91.
21. Wiroth JB, Filippi J, Schneider SM, et al,. Muscle performance in patients with Crohn's disease in clinical remission. Inflamm Bowel Dis 2005; 11: 296-303.
22. Katznelson L, Fairfield WP, Zeizafoun N, et al,. Effects of growth hormone secretion on body composition in patients with Crohn's disease. J Clin Endocrinol Metab 2003; 88: 5468-72.
23. Jahnsen J, Falch JA, Mowinckel P, Aadland E,. Body composition in patients with inflammatory bowel disease: a population-based study. Am J Gastroenterol 2003; 98: 1556-62.
24. Geerling BJ, Badart-Smook A, Stockbrugger RW, Brummer RJ,. Comprehensive nutritional status in recently diagnosed patients with inflammatory bowel disease compared with population controls. Eur J Clin Nutr 2000; 54: 514-21.
25. Geerling BJ, Lichtenbelt WD, Stockbrugger RW, Brummer RJ,. Gender specific alterations of body composition in patients with inflammatory bowel disease compared with controls. Eur J Clin Nutr 1999; 53: 479-85.
26. Capristo E, Mingrone G, Addolorato G, Greco AV, Gasbarrini G,. Glucose metabolism and insulin sensitivity in inactive inflammatory bowel disease. Aliment Pharmacol Ther 1999; 13: 209-17.
27. Ulivieri FM, Lisciandrano D, Ranzi T, et al,. Bone mineral density and body composition in patients with ulcerative colitis. Am J Gastroenterol 2000; 95: 1491-4.
28. Ulivieri FM, Piodi LP, Taioli E, et al,. Bone mineral density and body composition in ulcerative colitis: a six-year follow-up. Osteoporos Int 2001; 12: 343-8.
29. Mingrone G, Capristo E, Greco AV, et al,. Elevated diet-induced thermogenesis and lipid oxidation rate in Crohn disease. Am J Clin Nutr 1999; 69: 325-30.
30. Mingrone G, Benedetti G, Capristo E, et al,. Twenty-four-hour energy balance in Crohn disease patients: metabolic implications of steroid treatment. Am J Clin Nutr 1998; 67: 118-23.
31. Capristo E, Mingrone G, Addolorato G, Greco AV, Gasbarrini G,. Metabolic features of inflammatory bowel disease in a remission phase of the disease activity. J Intern Med 1998; 243: 339-47.
32. Geerling BJ, Badart-Smook A, Stockbrugger RW, Brummer RJ,. Comprehensive nutritional status in patients with long-standing Crohn disease currently in remission. Am J Clin Nutr 1998; 67: 919-26.
33. Capristo E, Addolorato G, Mingrone G, Greco AV, Gasbarrini G,. Effect of disease localization on the anthropometric and metabolic features of Crohn's disease. Am J Gastroenterol 1998; 93: 2411-9.
34. Tjellesen L, Nielsen PK, Staun M,. Body composition by dual-energy X-ray absorptiometry in patients with Crohn's disease. Scand J Gastroenterol 1998; 33: 956-60.
35. Mingrone G, Greco AV, Benedetti G, et al,. Increased resting lipid oxidation in Crohn's disease. Dig Dis Sci 1996; 41: 72-6.
36. Carlsson E, Bosaeus I, Nordgren S,. Body composition in patients with an ileostomy and inflammatory bowel disease: validation of bio-electric impedance spectroscopy (BIS). Eur J Clin Nutr 2002; 56: 680-6.
37. Royall D, Greenberg GR, Allard JP, Baker JP, Harrison JE, Jeejeebhoy KN,. Critical assessment of body-composition measurements in malnourished subjects with Crohn's disease: the role of bioelectric impedance analysis. Am J Clin Nutr 1994; 59: 325-30.
38. Kim J, Wang Z, Heymsfield SB, Baumgartner RN, Gallagher D,. Total-body skeletal muscle mass: estimation by a new dual-energy X-ray absorptiometry method. Am J Clin Nutr 2002; 76: 378-83.
39. Albanese CV, Diessel E, Genant HK,. Clinical applications of body composition measurements using DXA. J Clin Densitom 2003; 6: 75-85.
40. Thayu M, Shults J, Burnham JM, Zemel BS, Baldassano RN, Leonard MB,. Gender differences in body composition deficits at diagnosis in children and adolescents with Crohn's disease. Inflamm Bowel Dis 2007; 13: 1121-8.
41. Burnham JM, Shults J, Semeao E, et al,. Body-composition alterations consistent with cachexia in children and young adults with Crohn disease. Am J Clin Nutr 2005; 82: 413-20.
42. Hebuterne X, Filippi J, Al-Jaouni R, Schneider S,. Nutritional consequences and nutrition therapy in Crohn's disease. Gastroenterol Clin Biol 2009; 33 (Suppl. 3): S235-44.
43. Bannerman E, Davidson I, Conway C, Culley D, Aldhous MC, Ghosh S,. Altered subjective appetite parameters in Crohn's disease patients. Clin Nutr 2001; 20: 399-405.
44. Valentini L, Schulzke JD,. Mundane, yet challenging: the assessment of malnutrition in inflammatory bowel disease. Eur J Intern Med 2011; 22: 13-5.
45. Gerasimidis K, McGrogan P, Edwards CA,. The aetiology and impact of malnutrition in paediatric inflammatory bowel disease. J Hum Nutr Diet 2011; 24: 313-26.
46. Rocha R, Santana GO, Almeida N, Lyra AC,. Analysis of fat and muscle mass in patients with inflammatory bowel disease during remission and active phase. Br J Nutr 2009; 101: 676-9.
47. Thayu M, Denson LA, Shults J, et al,. Determinants of changes in linear growth and body composition in incident pediatric Crohn's disease. Gastroenterology 2010; 139: 430-8.
48. Ma K, Mallidis C, Bhasin S, et al,. Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am J Physiol Endocrinol Metab 2003; 285: E363-71.
49. Capristo E, De Gaetano A, Mingrone G, et al,. Multivariate identification of metabolic features in inflammatory bowel disease. Metabolism 1999; 48: 952-6.
50. Muller MJ, Schmidt LU, Korber J, von zur Muhlen A, Canzler H, Schmidt FW,. Reduced metabolic efficiency in patients with Crohn's disease. Dig Dis Sci 1993; 38: 2001-9.
51. Wiskin AE, Wootton SA, Cornelius VR, Afzal NA, Elia M, Beattie RM,. No relation between disease activity measured by multiple methods and REE in childhood Crohn disease. J Pediatr Gastroenterol Nutr 2012; 54: 271-6.
52. Schneeweiss B, Lochs H, Zauner C, et al,. Energy and substrate metabolism in patients with active Crohn's disease. J Nutr 1999; 129: 844-8.
53. Azcue M, Rashid M, Griffiths A, Pencharz PB,. Energy expenditure and body composition in children with Crohn's disease: effect of enteral nutrition and treatment with prednisolone. Gut 1997; 41: 203-8.
54. Cormier K, Mager D, Bannister L, et al,. Resting energy expenditure in the parenterally fed pediatric population with Crohn's disease. JPEN J Parenter Enteral Nutr 2005; 29: 102-7.
55. Hill RJ, Cleghorn GJ, Withers GD, et al,. Resting energy expenditure in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 45: 342-6.
56. Kushner RF, Schoeller DA,. Resting and total energy expenditure in patients with inflammatory bowel disease. Am J Clin Nutr 1991; 53: 161-5.
57. Haderslev KV, Jeppesen PB, Sorensen HA, Mortensen PB, Staun M,. Body composition measured by dual-energy X-ray absorptiometry in patients who have undergone small-intestinal resection. Am J Clin Nutr 2003; 78: 78-83.
58. Vaisman N, Dotan I, Halack A, Niv E,. Malabsorption is a major contributor to underweight in Crohn's disease patients in remission. Nutrition 2006; 22: 855-9.
59. Sousa Guerreiro C, Cravo M, Costa AR, et al,. A comprehensive approach to evaluate nutritional status in Crohn's patients in the era of biologic therapy: a case-control study. Am J Gastroenterol. 2007; 102: 2551-6.
60. Al-Jaouni R, Schneider SM, Piche T, Rampal P, Hebuterne X,. Effect of steroids on energy expenditure and substrate oxidation in women with Crohn's disease. Am J Gastroenterol 2002; 97: 2843-9.
61. Steiner SJ, Noe JD, Denne SC,. Corticosteroids increase protein breakdown and loss in newly diagnosed pediatric Crohn disease. Pediatr Res 2011; 70: 484-8.
62. Moller J, Jensen MB, Frandsen E, Moller N, Kissmeyer P, Laurberg S,. Growth hormone treatment improves body fluid distribution in patients undergoing elective abdominal surgery. Clin Endocrinol (Oxf) 1998; 49: 597-602.
63. Jensen MB, Kissmeyer-Nielsen P, Laurberg S,. Perioperative growth hormone treatment increases nitrogen and fluid balance and results in short-term and long-term conservation of lean tissue mass. Am J Clin Nutr 1998; 68: 840-6.
64. Ellegard L, Bosaeus I, Nordgren S, Bengtsson BA,. Low-dose recombinant human growth hormone increases body weight and lean body mass in patients with short bowel syndrome. Ann Surg 1997; 225: 88-96.
65. Kissmeyer-Nielsen P, Jensen MB, Laurberg S,. Perioperative growth hormone treatment and functional outcome after major abdominal surgery: a randomized, double-blind, controlled study. Ann Surg 1999; 229: 298-302.
66. Silvennoinen JA, Lehtola JK, Niemela SE,. Smoking is a risk factor for osteoporosis in women with inflammatory bowel disease. Scand J Gastroenterol 1996; 31: 367-71.
67. Thomas GA, Rhodes J, Green JT,. Inflammatory bowel disease and smoking-a review. Am J Gastroenterol 1998; 93: 144-9.
68. Jensen EX, Fusch C, Jaeger P, Peheim E, Horber FF,. Impact of chronic cigarette smoking on body composition and fuel metabolism. J Clin Endocrinol Metab 1995; 80: 2181-5.
69. Cosnes J,. Smoking, physical activity, nutrition and lifestyle: environmental factors and their impact on IBD. Dig Dis 2010; 28: 411-7.
70. Johnson GJ, Cosnes J, Mansfield JC,. Review article: smoking cessation as primary therapy to modify the course of Crohn's disease. Aliment Pharmacol Ther 2005; 21: 921-31.
71. Weakley FL, Turnbull RB,. Recognition of regional ileitis in the operating room. Dis Colon Rectum 1971; 14: 17-23.
72. Sheehan AL, Warren BF, Gear MW, Shepherd NA,. Fat-wrapping in Crohn's disease: pathological basis and relevance to surgical practice. Br J Surg 1992; 79: 955-8.
73. Desreumaux P, Ernst O, Geboes K, et al,. Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology 1999; 117: 73-81.
74. Peyrin-Biroulet L, Chamaillard M, Gonzalez F, et al,. Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander? Gut 2007; 56: 577-83.
75. Yamamoto K, Kiyohara T, Murayama Y, et al,. Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn's disease. Gut 2005; 54: 789-96.
76. Olivier I, Theodorou V, Valet P, et al,. Is Crohn's creeping fat an adipose tissue? Inflamm Bowel Dis 2011; 17: 747-57.
77. Drouet M, Dubuquoy L, Desreumaux P, Bertin B,. Visceral fat and gut inflammation. Nutrition 2012; 28: 113-7.
78. Peyrin-Biroulet L, Gonzalez F, Dubuquoy L, et al,. Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. Gut 2012; 61: 78-85.
79. Batra A, Heimesaat MM, Bereswill S, et al,. Mesenteric fat-control site for bacterial translocation in colitis? Mucosal Immunol 2012; 5: 580-91.
80. Batra A, Pietsch J, Fedke I, et al,. Leptin-dependent toll-like receptor expression and responsiveness in preadipocytes and adipocytes. Am J Pathol 2007; 170: 1931-41.
81. Charriere G, Cousin B, Arnaud E, et al,. Preadipocyte conversion to macrophage evidence of plasticity. J Biol Chem 2003; 278: 9850-5.
82. Nic Suibhne T, Raftery TC, McMahon O, Walsh C, O'Morain C, O'Sullivan M., High prevalence of overweight and obesity in adults with Crohn's disease: associations with disease and lifestyle factors. J Crohns Colitis 2012; doi: 10.1016/j.crohns.2012.09.009.
83. Correia M, Cravo M, Marques-Vidal P, et al,. Serum concentrations of TNF-alpha as a surrogate marker for malnutrition and worse quality of life in patients with gastric cancer. Clin Nutr 2007; 26: 728-35.
84. Steed H, Walsh S, Reynolds N,. A brief report of the epidemiology of obesity in the inflammatory bowel disease population of Tayside, Scotland. Obes Facts 2009; 2: 370-2.
85. Long MD, Crandall WV, Leibowitz IH, et al,. Prevalence and epidemiology of overweight and obesity in children with inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 2162-8.
86. Chan SS, Luben R, Olsen A, et al,. Body mass index and the risk for Crohn's disease and ulcerative colitis: data from a European prospective cohort study (The IBD in EPIC study). Am J Gastroenterol 2013; 108: 575-82.
87. Blain A, Cattan S, Beaugerie L, Carbonnel F, Gendre JP, Cosnes J,. Crohn's disease clinical course and severity in obese patients. Clin Nutr 2002; 21: 51-7.
88. Bultman E, de Haar C, van Liere-Baron A, et al,. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients. Aliment Pharmacol Ther 2012; 35: 335-41.
89. Nakahigashi M, Yamamoto T,. Increases in body mass index during infliximab therapy in patients with Crohn's disease: an open label prospective study. Cytokine 2011; 56: 531-5.
90. Wiese D, Lashner B, Seidner D,. Measurement of nutrition status in Crohn's disease patients receiving infliximab therapy. Nutr Clin Pract 2008; 23: 551-6.
91. Causey MW, Johnson EK, Miller S, Martin M, Maykel J, Steele SR,. The impact of obesity on outcomes following major surgery for Crohn's disease: an American College of Surgeons National Surgical Quality Improvement Program assessment. Dis Colon Rectum 2011; 54: 1488-95.
92. Krane MK, Allaix ME, Zoccali M, et al,. Does morbid obesity change outcomes after laparoscopic surgery for inflammatory bowel disease? Review of 626 consecutive cases. J Am Coll Surg 2013; 216: 986-96.
93. Woo J, Ho SC, Sham A,. Longitudinal changes in body mass index and body composition over 3 years and relationship to health outcomes in Hong Kong Chinese age 70 and older. J Am Geriatr Soc 2001; 49: 737-46.
94. Janssen I, Baumgartner RN, Ross R, Rosenberg IH, Roubenoff R,. Skeletal muscle cutpoints associated with elevated physical disability risk in older men and women. Am J Epidemiol 2004; 159: 413-21.
95. Van Langenberg DR, Russell AP, Gibson PR,. Factors in Crohn's disease important in maintaining the integrity of muscle: the forgotten cousin of bone. J Gastroenterol Hepatol 2011; 26 (Suppl. 4): 57.
96. Selinger CP, Andrews JM,. Mortality in a large Australian metropolitan cohort of ulcerative colitis patients. J Gastroenterol Hepatol. 2011; 26 (Suppl. 4): 56.
97. Burnham JM, Shults J, Semeao E, et al,. Whole body BMC in pediatric Crohn disease: independent effects of altered growth, maturation, and body composition. J Bone Miner Res 2004; 19: 1961-8.
98. Cravo M, Guerreiro CS, dos Santos PM, et al,. Risk factors for metabolic bone disease in Crohn's disease patients. Inflamm Bowel Dis 2010; 16: 2117-24.
99. Lee N, Radford-Smith GL, Forwood M, Wong J, Taaffe DR,. Body composition and muscle strength as predictors of bone mineral density in Crohn's disease. J Bone Miner Metab 2009; 27: 456-63.
100. Mauro M, Armstrong D,. Evaluation of densitometric bone-muscle relationships in Crohn's disease. Bone 2007; 40: 1610-4.
101. Leslie WD, Miller N, Rogala L, Bernstein CN,. Body mass and composition affect bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD cohort study. Inflamm Bowel Dis 2009; 15: 39-46.
102. Werkstetter KJ, Pozza SB, Filipiak-Pittroff B, et al,. Long-term development of bone geometry and muscle in pediatric inflammatory bowel disease. Am J Gastroenterol 2011; 106: 988-98.
103. Dubner SE, Shults J, Baldassano RN, et al,. Longitudinal assessment of bone density and structure in an incident cohort of children with Crohn's disease. Gastroenterology 2009; 136: 123-30.
104. van Langenberg DR, Gibson PR,. Systematic review: fatigue in inflammatory bowel disease. Aliment Pharmacol Ther 2010; 32: 131-43.
105. Norman K, Kirchner H, Lochs H, Pirlich M,. Malnutrition affects quality of life in gastroenterology patients. World J Gastroenterol 2006; 12: 3380-5.
106. Addolorato G, Capristo E, Stefanini GF, Gasbarrini G,. Inflammatory bowel disease: a study of the association between anxiety and depression, physical morbidity, and nutritional status. Scand J Gastroenterol 1997; 32: 1013-21.
107. Kelly TL, Wilson KE, Heymsfield SB,. Dual energy X-ray absorptiometry body composition reference values from NHANES. PLoS ONE 2009; 4: e7038.